Skip to main content

Table 2 Plasma lipids

From: Effect of simvastatin on bone markers in osteopenic women: a placebo-controlled, dose-ranging trial [ISRCTN85429598]

 

Placebo

Simvastatin 20 mg

Simvastatin 40 mg

 

Baseline

12 weeks

Baseline

12 weeks

Baseline

12 weeks

Total cholesterol, mmol/L

5.69 ± 0.49

5.53 ± 0.49

6.08 ± 0.52

4.55 ± 0.26

5.28 ± 0.36

3.88 ± 0.21a

Triglycerides, mmol/L

1.13 ± 0.17

1.21 ± 0.15

0.88 ± 0.06

0.96 ± 0.10

0.90 ± 0.15

0.84 ± 0.16

HDL-cholesterol, mmol/L

1.60 ± 0.08

1.78 ± 0.08

1.60 ± 0.16

1.63 ± 0.18

1.76 ± 0.13

1.84 ± 0.13

LDL-cholesterol, mmol/L

3.54 ± 0.47

3.28 ± 0.39

4.09 ± 0.57

2.48 ± 0.36

3.10 ± 0.34

1.63 ± 0.13a,b

  1. Mean ± SE ap < 0.01 vs placebo b p < 0.05 vs simvastatin 20 mg
Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us